Shibata S, Chow W, Frankel P, Leong L, Lim D, Longmate J, Margolin K, McNamara M, Morgan R, Raschko J, Somlo G, Synold T, Tetef M, Twardowski P, Yen Y, Doroshow J, Lenz H, Gandara D. A phase I trial of oxaliplatin (OX) in combination with gemcitabine (G): A California Consortium Trial. Proc. Amer. Soc. Clin. Oncol. 20: 96a, 2001.
Morgan R, Doroshow J, Synold T, Lim D, Shibata S, Margoln K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, PazB, Chu D, Frankel P. Phase I trial of intraperitoneal Iip) doecetaxel (D) in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Proc. Amer. Soc. Clin. Oncol. 20: 93b, 2001.
Newman EM, Longmate JA, Lenz H.-J, Carroll MI, Stalter SK, Lim D, Raschko JW, Shibata SI, Somlo G, Doroshow JH. Phase I and pharmacokinetic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2’-deoxycytidine: a California Cancer Consortium study. Proc. Amer. Soc. Clin. Oncol. 21: 108a, #431, 2002.
Doroshow JH, Margolin K, Chow W, Leong L, Lim D, McNamara M, Morgan R, Shibata S, Somlo G, Twardowski P, Weitzel J, Yen Y, Kogut N, Schriber J, Alvarnas J, Stalter S. High-dose chemotherapy with autologous stem cell rescue (PSCT) for relapsed nonseminomatous germ cell cancer (NSGCT): Effective salvage for poor-risk patients (pts) in first relapse. Proc. Amer. Soc. Clin. Oncol 21: 179a, # 714, 2002.
Morgan, R.J., Doroshow, J.H., Synold, T., Lim, D., Shibata, S., Margolin, K.A., Schwarz, R., Leong, L., Somlo, G., Twardowski, P., Yen, Y., Chow, W., Lin, P., Paz, B., Chu, D., Frankel, P. and Stalter S. Phase I trial of intraperitoneal (ip) docetaxel (D) in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity (DLT) and pharmacokinetics (PK). Proc. Amer. Assoc. Cancer Res. 43: 551, #2741, 2002.
Shibata S, Frankel P, Leong L, Lim D, Margolin K, Morgan R, Somlo G, Synold T, Twardowski P, Doroshow JD. Phase I study of cisplatin (CDDP) in combination with ICRF-187 (ICRF) in the treatment of advanced malignancies. Proc. Amer. Soc. Clin. Oncol. 22: 164, 2003.
Morgan RJ, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, and Stalter S. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res. 9: 461-467, 2004.
Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas J, Kogut N, Schriber J, Fermin E, Damon L, and Doroshow JH. Prognostic indicators and survival in 120 patients with stage IIIB inflammatory breast carcinoma following dose-intense chemotherapy. J. Clin. Oncol. 22: 1839-1848, 2004.
Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Kadhimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Jr, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, and Doroshow JH. Feasibility study of concurrent infusional dexrazoxane and dose-intensive doxorubicin administered over 96 hours for the treatment of advanced malignancies. Cancer Chemother. Pharmacol. 54: 241-248, 2004.
Lim D, Akman S, Margolin K, Carr BI, Leong L, Odujinrin O, Morgan RJ Jr, and Doroshow JH. Phase I trial of synkayvite (Vitamin K3, Menadiol Diphosphate) in advanced malignancy. Invest. New Drugs 23: 235-239, 2005.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported. Last updated: 10/05.
